3 years ago

Clinicopathologic Characteristics and Outcomes of Transformed Diffuse Large B-Cell Lymphoma in Hepatitis C Virus-Infected Patients

Harrys A. Torres, Jeff Hosry, Minas P. Economides, Felipe Samaniego, Roberto N. Miranda
Hepatitis C virus (HCV) causes a chronic but curable infection associated with the development of marginal zone lymphoma (MZL) and diffuse large B-cell lymphoma (DLBCL). Preliminary data have shown frequent transformation of indolent lymphoma to DLBCL in HCV-infected patients. To compare their clinicopathologic characteristics and oncologic outcomes, we reviewed the medical records and pathology reports of HCV-infected and uninfected patients with DLBCL that transformed from indolent lymphoma seen at The University of Texas MD Anderson Cancer Center (June 2004-May 2015). To identify predictors of DLBCL relapse, patients with relapse after first-line chemotherapy were compared with those without it using univariate and logistic regression analyses. Compared with the uninfected patients (n=63), HCV-infected patients (n=21) were younger (median age =54 years [interquartile range= 49-62 years] vs 62 years [53-66 years]; p= 0.01) and more often had advanced DLBCL (Ann Arbor stage 3-4; 95% vs 76%; p= 0.05). Immunophenotypically, more HCV-infected than uninfected patients had CD10-negative B cells (76% vs 43%; p= 0.008), CD5-positive B cells (39% vs 7%; p= 0.004), and activated B-cell phenotypes (57% v 31%; p= 0.07). Comparison of the patients who had relapse after first-line chemotherapy (n= 42) and those who did not (n= 40) revealed that having CD5-positive B cells was the only factor associated with DLBCL relapse in multivariate analysis (odds ratio= 10.7; p= 0.02). HCV-infected patients with transformed DLBCL have unique clinicopathologic characteristics that make their lymphoma difficult to treat, potentially leading to unfavorable outcome. The impact of HCV eradication should be explored in such patients. This article is protected by copyright. All rights reserved.

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1002/ijc.31110

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.